Frontage HoldingsFGHQF -3.57%58 Return-on-Tangible-Equity is 5.94% as of Dec. 2025, which is 42% below its 10-year median of 10.24. GuruFocus rates FGHQF with a GF Score™ of 58/100 and a GF Value™ of $0.23 (Significantly Undervalued). The stock has 8 warning signs investors should review. Among 1,199 Biotechnology companies, Frontage Holdings ranks better than 82.24% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Frontage Holdings's annualized net income for the quarter that ended in Dec. 2025 was $7.7 Mil. Frontage Holdings's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $130.1 Mil. Therefore, Frontage Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 5.94%.
The historical rank and industry rank for Frontage Holdings's Return-on-Tangible-Equity or its related term are showing as below:
FGHQF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 0.66 Med: 10.24 Max: 41.6
Current: 5.42
During the past 10 years, Frontage Holdings's highest Return-on-Tangible-Equity was 41.60%. The lowest was 0.66%. And the median was 10.24%.
FGHQF's Return-on-Tangible-Equity is ranked better than 82.24% of 1199
companies
in the Biotechnology industry
Industry Median: -42.21
vs FGHQF: 5.42
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Frontage Holdings Return-on-Tangible-Equity Related Terms
Frontage Holdings Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Frontage Holdings's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FGHQF vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Frontage Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Frontage Holdings Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Frontage Holdings's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Frontage Holdings's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 5.94% mean?
Frontage Holdings (FGHQF) has a Return-on-Tangible-Equity of 5.94% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Frontage Holdings and its competitors. This is 42% below median its historical median of 10.24. Over the past decade, Frontage Holdings' Return-on-Tangible-Equity has ranged from 0.66 to 41.60. According to the industry distribution chart, Frontage Holdings ranks #213 out of 1199 companies in the Biotechnology industry, placing it in the top 17.8%.
Is Frontage Holdings' Return-on-Tangible-Equity too high?
Frontage Holdings' current Return-on-Tangible-Equity of 5.94% is 42% below median its 10-year median of 10.24. Over the past 10 years, this metric has ranged from a low of 0.66 to a high of 41.60. Based on the distribution chart, Frontage Holdings ranks #213 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Frontage Holdings has a GF Score™ of 58/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Frontage Holdings' Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Frontage Holdings ranks #213 out of 1199 companies for Return-on-Tangible-Equity. This places Frontage Holdings in the top 18% of its industry — outperforming the majority of peers. Historically, Frontage Holdings' own Return-on-Tangible-Equity has ranged from 0.66 to 41.60 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Frontage Holdings and its competitors. Frontage Holdings's current Return-on-Tangible-Equity is 5.94%, which is 42% below median its own 10-year median of 10.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Frontage Holdings stock overvalued right now?
Based on GuruFocus' analysis, Frontage Holdings (FGHQF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.23, compared to a current price of $0.14 — trading 41.3% below its estimated fair value. The current Return-on-Tangible-Equity is 5.94%, which is 42% below median its 10-year median of 10.24. Frontage Holdings' overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Frontage Holdings (FGHQF), the current Return-on-Tangible-Equity is 5.94% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Frontage Holdings (FGHQF) Overvalued in 2026?
Based on GuruFocus' analysis, Frontage Holdings stock appears to be undervalued.
The current stock price of $0.14 is trading 41.3% below its estimated GF Value™ of $0.23.
GuruFocus considers Frontage Holdings to be Significantly Undervalued.
Key valuation signals for FGHQF:
Return-on-Tangible-Equity: 5.94% (42% below median its 10-year median of 10.24)
GF Value™: $0.23 vs. price of $0.14 (41.3% below fair value)
No single metric tells the full story. See the FGHQF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Frontage Holdings Corp provides laboratory and related services to pharmaceutical and agrochemical companies. Its segments include North America and Europe segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the USA, Canada and Europe; and PRC segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the PRC. It derives majority of the revenue from North America and Europe segment. Geographically majority of the revenue is derived from USA and Canada.
58GF Score
Get the complete analysis for FGHQF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FGHQF has been successfully added to your 
